Genmab Reports Results of Darzalex (daratumumab) in P-III COLUMBA Study for Patients with R/R Multiple Myeloma

 Genmab Reports Results of Darzalex (daratumumab) in P-III COLUMBA Study for Patients with R/R Multiple Myeloma

Genmab Reports Results of Darzalex (daratumumab) in P-III COLUMBA Study for Patients with R/R Multiple Myeloma

Shots:

  • The P-III COLUMBA (NCT03277105) study involves assessing of Darzalex (SC) + recombinant human hyaluronidase PH20 (2000 U/mL) vs Darzalex (IV) in 522 patients with r/r multiple myeloma
  • The P-III COLUMBA study results: ORR (41.1% vs 37.1%); geometric mean of Maximum Trough concentration (Ctrough) (499 mg/mL vs 463 mg/mL); no new safety signals
  • Darzalex (daratumumab) is IgG1k mAb, with broad spectrum cytotoxic activity targeting CD38 and has received two BT designation from FDA as monothx & combination therapy. In Aug,2012 Janssen Biotech collaborated with Genmab to develop and commercialise daratumumab

Click here to read full press release/ article | Ref: Genmab | Image: Pharma News

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post